Signal
CellCentric secures $220M Series D to advance multiple myeloma drug through late-stage trials
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-05-06 11:00 UTCUpdated 2026-05-06 11:18 UTC
rss
clinical_trialsbiotech_fundingdrug_development
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
CellCentric has raised $220 million in a Series D funding round led by Venrock to support ongoing Phase 2 and planned Phase 3 clinical trials of inobrodib, an oral drug targeting multiple myeloma.
Entities
CellCentricVenrockinobrodibWill West
Score total
0.96
Momentum 24h
2
Posts
2
Origins
2
Source types
1
Duplicate ratio
0%
Why now
- Recent funding round reflects investor confidence in CellCentric's clinical progress and strategy.
- Phase 2 studies are ongoing with Phase 3 trials planned, marking a pivotal development stage.
- Potential IPO signals readiness to scale operations and increase market presence.
Why it matters
- The funding enables CellCentric to advance late-stage clinical trials for a novel multiple myeloma therapy.
- Supporting independence, the capital positions CellCentric to control its drug development and commercialization path.
- Progress in multiple myeloma treatments addresses a critical need for patients with persistent disease.
LLM analysis
Topic mix: lowPromo risk: lowSource quality: high
Recurring claims
- CellCentric raised $220 million in a Series D round led by Venrock to support clinical trials of an oral multiple myeloma drug.
- The funding will support ongoing Phase 2 and planned Phase 3 trials of inobrodib, aiming to bring a differentiated treatment to market.
How sources frame it
- Fierce Biotech: neutral
All evidence
All evidence
In the last three years, CellCentric CEO Will West has been on a journey that has transformed how he thinks about the future of his company. He used to be “obsessed with pharma ...
Fierce Biotech · fiercebiotech.com · 2026-05-06 11:18 UTC
CellCentric raises $220M for a ‘transformative’ multiple myeloma medicine
BioPharma Dive · biopharmadive.com · 2026-05-06 11:00 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- Fierce Biotech (1)
- BioPharma Dive (1)
Top origin domains (this list)
- fiercebiotech.com (1)
- biopharmadive.com (1)